Esperion Therapeutics (ESPR) has two upcoming PDUFA dates scheduled at the end of February for their bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are expected to treat elevated low-density lipoprotein cholesterol "LDL-C". Both of these product candidates have sailed through their regulatory pathway and have been tested in multiple sub-populations. If approved, both of these products will be entering a multi-billion dollar hyperlipidemia U.S. market (Figure 1), which hasn't seen new non-statin LDL-C lowering drug in almost 20 years.
Figure 1: Market Opportunity [Source: ESPR]
I